Lai A Fat Esther J S K, Vrede Martinus A, Soetosenojo Ramon M, Lai A Fat Rudy F M
Departments of Dermatology and Pathology, Academic Hospital Paramaribo, Surinam.
Int J Dermatol. 2002 Nov;41(11):796-800. doi: 10.1046/j.1365-4362.2002.01633.x.
BACKGROUND: Cutaneous leishmaniasis is an endemic disease in Surinam. The disease was treated until the early 1970s with pentavalent antimony. Pentamidine mesylate was introduced by Niemel in 1973 for the treatment of cutaneous leishmaniasis in Surinam. MATERIALS AND METHODS: In this retrospective study, we evaluate the results of treatment with pentamidine mesylate in 235 patients and with pentamidine isethionate in 80 patients. RESULTS: In the pentamidine mesylate- and pentamidine isethionate-treated groups, a cure rate (healing without relapse) of nearly 90% was found. Relapses were seen in approximately 10% of patients in both groups. Minor side-effects, such as pain at the injection site, bitter taste, and nausea, were seen with both drugs in about 65% of patients. Complaints of the respiratory tract were seen in less than 10% of patients in the pentamidine isethionate-treated group, but were uncommon in the pentamidine mesylate-treated group. CONCLUSIONS: Pentamidine mesylate and isethionate have similar safety, efficacy, and side-effect profiles in the treatment of cutaneous leishmaniasis in Surinam.
背景：皮肤利什曼病是苏里南的一种地方病。直到20世纪70年代初，该病一直用五价锑进行治疗。1973年，尼梅勒引入甲磺酸喷他脒用于治疗苏里南的皮肤利什曼病。 材料与方法：在这项回顾性研究中，我们评估了235例使用甲磺酸喷他脒治疗的患者和80例使用乙磺酸盐喷他脒治疗的患者的治疗结果。 结果：在甲磺酸喷他脒治疗组和乙磺酸盐喷他脒治疗组中，发现治愈率（治愈且无复发）接近90%。两组中约10%的患者出现复发。两种药物在约65%的患者中都出现了轻微副作用，如注射部位疼痛、口苦和恶心。在乙磺酸盐喷他脒治疗组中，不到10%的患者出现呼吸道不适，但在甲磺酸喷他脒治疗组中并不常见。 结论：在苏里南治疗皮肤利什曼病时，甲磺酸喷他脒和乙磺酸盐喷他脒具有相似的安全性、疗效和副作用特征。
Int J Dermatol. 2002-11
Rev Soc Bras Med Trop. 1996
J Antimicrob Chemother. 2003-5
PLoS Negl Trop Dis. 2025-1-3
Pathogens. 2024-9-27
ACS Appl Mater Interfaces. 2024-9-18
Curr Drug Discov Technol. 2025
Front Mol Biosci. 2023-4-21
Microorganisms. 2021-12-2
Zotero 插件